The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine

European Journal of Clinical Pharmacology

Volumn 55, Issue 1, 1999, Pages 57-60

  Heinig, R ^a   Adelmann, H G ^a   Ahr, G ^a  

^a BAYER AG   (Germany)

Author keywords

Bioavailability; Cytochrome P450 3A4 First pass metabolism; Enzyme inhibition

Indexed keywords

CYTOCHROME P450 3A4; DRUG METABOLITE; KETOCONAZOLE; NISOLDIPINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FIRST PASS EFFECT; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADULT; ANTIFUNGAL AGENTS; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DRUG INTERACTIONS; HUMANS; KETOCONAZOLE; MALE; NISOLDIPINE; TIME FACTORS;

EID: 0033038165     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050593     Document Type: Article

References (22)

1. Friedel HA, Sorkin EM (1988) Nisoldipine: a preliminary review of its pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 36: 682-731
2. Plosker GL, Faulds D (1996) Nisoldipine coat-core: a review of its pharmacology and therapeutic efficacy in hypertension. Drugs 52: 232-253
3. Anonymous (1997) Nisoldipine modified-release: another long-acting calcium antagonist formulation (Editorial). Drugs Ther Perspect 9: 1-5
4. Melcher A, Dens J, Curry P, et al (1997) Nisoldipine CC: clinical experience in ischaemic heart disease. Cardiology 88 (Suppl. 1): 17-23
5. Scherling D, Karl W, Ahr G, et al (1988) Pharmacokinetics of nisoldipine: III. Biotrans formation of nisoldipine in rat, dog, monkey, and man. Drug Res 38: 1105-1110
6. Scherling D, Ahr G, Karl W (1987) Biotransformation of nisoldipine in man. In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987 Springer, Berlin Heidelberg New York, pp 85-88
7. Guengerich FP, Brian WR, Iwasaki M, et al (1991) Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450IIIA4. J Med Chem 34: 1838-1844
8. Hansten PD, Horn JR (1993) Calcium channel blocker drug interactions. Drug Interaction Newsletter 13: 605-610
9. Bailey DG, Arnold JMO, Strong HA, et al. (1993) Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 54: 589-594
10. Van Harten J, van Brummelen P, Lodewijks MTM, et al (1988) Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. Clin Pharmacol Ther 43: 332-341
11. Brendel E, Heinig R, Ahr G, et al (1992) Influence of cimetidine and ranitidine on the pharmacokinetics of controlled-release formulations of the two calcium-antagonists nifedipine and nisoldipine [Abstract]. Naunyn Schmiedebergs Arch Pharmacol 345 [Suppl 1]: R3
12. Honig PK, Wortham DC, Zamani K, et al (1993) Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 269: 1513-1518
13. Krishnaiah YSR, Satyanarayana S, Visweswaram D (1994) Interaction between tolbutamide and ketoconazole in healthy subjects. Br J Clin Pharmacol 37: 205-207
14. Jalava KM, Olkkola KT, Neuvonen PJ (1997) Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 61: 410-415
15. Neuvonen PJ, Jalava KM (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60: 54-61
16. Czyborra P, Kremens B, Brendel E, et al (1998) Fluconazole enhances blood pressure-lowering effects of nifedipine in a patient with malignant phaeochromocytoma (Abstract). Naunyn Schmiedebergs Arch Pharmacol 357 [Suppl]: R165
17. Anonymous (1994) COSTART: Coding symbols for thesaurus of adverse reaction terms. In: Adverse experience reporting requirements for human Drug and licensed biological products; proposed rule. Federal Register, 27 October 1994, pp 54046-54064
18. Van Harten J, Lodewijks MTM, Guyt-Scholten JW, et al (1987) Gas chromatographic determination of nisoldipine and one of its metabolites in plasma. J Chromatogr 423: 327-333
19. Ahr G, Wingender W, Kuhlmann J (1987) Pharmacokinetics of nisoldipine. In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987 Springer, Berlin Heidelberg New York, pp 59-66
20. Anonymous (1987) Pharmakokinetische und pharmakodynamische Daten von Nisoldipin [Editorial]. Fortschr Med 105 [Suppl.] 30: 7-9
21. Schaefer HG, Heinig R, Ahr G, et al (1997) Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. Eur J Clin Pharmacol 51: 473-480
22. Heinig R, Ahr G, Hayauchi Y, et al (1997) Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation. Int J Clin Pharmacol Ther 35: 341-351